Recommended Pages at thepharmaletter.com
Eisai breast cancer drug still viewed as not cost effective by NICE - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence (NICE) has issued new guidance not recommending Halaven (eribulin), from Japanese drug major Eisai (TYO: 4523), for the treatment of locally advanced or m” View full resource at thepharmaletter.com
Most Recently Shared on April 3, 2012 at 12:13 pm By:
Even w/discount MT @ThePharmaLetter: NICE still views Eisai breast cancer drug Halaven as not cost effective http://t.co/Bkd28AWx #pharma
Relovair COPD and asthma filings on track despite more mixed trial results - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “As well as announcing new mixed clinical trial data, UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say that the registrational program for their investigational drug Relovair (fluticasone furoate and vilanterol (FF/VI” View full resource at thepharmaletter.com
Most Recently Shared on March 26, 2012 at 12:02 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Relovair COPD and asthma filings on track despite more mixed trial results http://t.co/iccTfECw
GSK and Theravance to file COPD/asthma drug - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) and partner USA-based Theravance (Nasdaq: THRX), in which GSK has acquired a 19% equity stake (The Pharma Letter November 30, 2010), said yesterday that they would submit regulatory filings for their once-daily i” View full resource at thepharmaletter.com
Most Recently Shared on January 10, 2012 at 1:12 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
GSK and Theravance to file COPD/asthma drug http://t.co/hpf3xBCi
Johnson & Johnson?s telaprevir approved in Europe for genotype-1 chronic hepatitis C - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “The European Commission has approved Johnson & Johnson (NYSE: JNJ) subsidiary Janssen?s Incivo (telaprevir), a direct acting antiviral (DAA) protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus (HCV), in combination with peginterf” View full resource at thepharmaletter.com
Most Recently Shared on September 22, 2011 at 11:39 am By:
RT @ThePharmaLetter: Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C http://t.co/WZExFTDH #pharma
India pharmaceutical industry up 16.9%; shows more signs of growth, BMI predicts - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “There is no doubt that the opportunity in the coming years will be from emerging markets, which have seen a wealth of activity from multinational drug majors. Among these, India's pharmaceutical market is booming and there is little chance of it slowing a” View full resource at thepharmaletter.com
Most Recently Shared on August 31, 2011 at 12:13 pm By:
More growth figs. for India. RT @ThePharmaLetter: Indian pharma up 16.9%; shows more signs of growth, BMI says http://t.co/RKyae4m #pharma
US FDA approves Pfizer lung cancer drug Xalkori and companion diagnostic from Abbott - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “The US Food and Drug Administration has approved global drugs behemoth Pfizer?s (NYSE: PFE) Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal ana” View full resource at thepharmaletter.com
Most Recently Shared on August 30, 2011 at 1:16 pm By:
Raymond DuBois Physician, Doctor, Internist, Gastroenterologist, and Health Executive
US FDA approves Pfizer lung cancer drug Xalkori and companion diagnostic - Pharmaceutical and Biotechnology News - http://t.co/kM4Y3VI
EU Commission clears KKR acquisition of Pfizer Capsugel unit; Meda says no approach from Valeant - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “Under European Union merger regulations, the European Commission has cleared the proposed acquisition of Capsugel by fund manager Kohlberg Kravis Roberts (KKR). Capsugel is being divested to KKR by US drugs behemoth Pfizer (NYSE: PFE) in a deal worth $2.3” View full resource at thepharmaletter.com
Most Recently Shared on July 28, 2011 at 2:17 pm By:
RT @ThePharmaLetter: EU Commission clears KKR acquisition of Pfizer Capsugel unit; Meda says no approach from Valeant http://bit.ly/qJNDpK
Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “US biotech Amylin Pharmaceuticals (Nasdaq: AMLN) saw its shares all 4.9% to $12.65 after it reported financial results for the quarter ended June 30, 2011 showing that GAAP net loss was $31.4 million, or $0.22 per share, compared to $44.2 million, or $0.3” View full resource at thepharmaletter.com
Most Recently Shared on July 27, 2011 at 11:49 am By:
RT @ThePharmaLetter: Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales http://bit.ly/nPuMfU #pharma
Sanofi debuts prostate cancer drug Jevtana in UK - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “French drug major Sanofi (Euronext: SAN) yesterday announced the UK launch of Jevtana (cabazitaxel), in combination with prednisone/prednisolone for the treatment of men with mHRPC previously treated with docetaxel.” View full resource at thepharmaletter.com
Most Recently Shared on July 5, 2011 at 10:43 am By:
Sanofi debuts prostate cancer drug Jevtana in UK http://bit.ly/lHx4YB
Joint ventures in generics to boost Indian pharma industry - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “The Indian pharmaceutical industry is moving towards the adoption and development of generic drugs, which will help it to grow at a compound annual growth rate (CAGR) of around 15% during the fiscal years 2012 through 2014, according to a new report from” View full resource at thepharmaletter.com
Most Recently Shared on June 23, 2011 at 1:03 am By:
Richard G. Lanzara Health Professional
RT @ThePharmaLetter Joint ventures in generics to boost Indian pharma industry http://t.co/2V1Mf2W #pharma #biotech
Pfizer?s Lyrica meets endpoint in Ph III study of central neuropathic pain after spinal cord injury - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “Global drugs behemoth Pfizer (NYSE: PFE) says its blockbuster neuropathic pain drug Lyrica (pregabalin) met its primary endpoint of positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo in a P” View full resource at thepharmaletter.com
Most Recently Shared on June 22, 2011 at 11:47 am By:
RT @ThePharmaLetter: Pfizer’s Lyrica meets endpoint in PhIII study of central neuropathic pain after spinal cord injury http://bit.ly/mStH0P
Active Biotech and Ipsen in broad partnership for TASQ in uro-oncology - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “Sweden's Active Biotech AB (NORDIC: ACTI) and Paris, France-based Ipsen (Euronext: IPN) have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound tasquinimod (TASQ). A global Phase III trial of TASQ in” View full resource at thepharmaletter.com
Most Recently Shared on April 20, 2011 at 9:46 am By:
john clay mchugh Surgeon, Urologist, Physician, and Doctor
Active Biotech and Ipsen in broad partnership for TASQ in uro-oncology (thepharmaletter.com): Swedens Active Bio... http://bit.ly/go4SII
GlaxoSmithKline drops Avodart for prostate cancer risk reduction - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer. The company will withdraw applications from regulatory review where procedures are on” View full resource at thepharmaletter.com
Most Recently Shared on March 24, 2011 at 5:35 pm By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction http://bit.ly/gRCa25
Alk-Abello in up to 60 million-euro deal with Torii for allergy products in Japan - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “Danish drugmaker Alk-Abello (ALKB: DC) has entered into an exclusive license agreement with Japan's Torii Pharmaceuticals (TSE: 4551) to develop and commercialize Alk's house dust mite allergy immunotherapy products for asthma and allergic rhinitis in Jap” View full resource at thepharmaletter.com
Most Recently Shared on February 8, 2011 at 1:41 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Alk-Abello in up to 60 million-euro deal with Torii for allergy products in Japan http://t.co/oqO70t3
Roche/Genentech license GlycArt's GA101 - Pharmaceutical industry news
thepharmaletter.com — “Roche/Genentech license GlycArt's GA101. roche/genentech, license, glycart, ga101, genentech, licensed, phase” View full resource at thepharmaletter.com
Most Recently Shared on December 5, 2010 at 8:29 pm By:
GA101, first type II glycoengineered mAb to enter clinical trials in #hematology malignancies http://bit.ly/frWY5L #ASH2010 ^lc
